NASDAQ:IRTC Irhythm Technologies Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Irhythm Technologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $227.15 +4.61 (+2.07 %) (As of 09/25/2020 02:07 PM ET) Add Compare Share Today's Range$220.34Now: $227.15▼$227.7350-Day Range$172.95MA: $207.34▼$233.3352-Week Range$56.24Now: $227.15▼$241.82Volume2,694 shsAverage Volume396,826 shsMarket Capitalization$6.22 billionP/E RatioN/ADividend YieldN/ABeta1.8 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. Its Zio XT monitor, a single-use, wire-free, and wearable patch-based biosensor, records patient's heartbeats and ECG data. The company was founded in 2006 and is headquartered in San Francisco, California.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingIrhythm Technologies has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $183.11, Irhythm Technologies has a forecasted downside of 19.1% from its current price of $226.30.Amount of Analyst CoverageIrhythm Technologies has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.9 Community Rank Outperform VotesIrhythm Technologies has received 331 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIrhythm Technologies has received 234 “underperform” votes. (Add your “underperform” vote.)Community SentimentIrhythm Technologies has received 58.58% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Irhythm Technologies and other stocks. Vote “Outperform” if you believe IRTC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IRTC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIrhythm Technologies does not currently pay a dividend.Dividend GrowthIrhythm Technologies does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Irhythm Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,118,563.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Irhythm Technologies is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Irhythm Technologies are expected to grow in the coming year, from ($2.10) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Irhythm Technologies is -91.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Irhythm Technologies is -91.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIrhythm Technologies has a P/B Ratio of 44.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.19 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IRTC Previous Symbol CUSIPN/A CIK1388658 Webwww.irhythmtech.com Phone415-632-5700Debt Debt-to-Equity Ratio0.94 Current Ratio3.10 Quick Ratio2.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$214.55 million Price / Sales29.01 Cash FlowN/A Price / Cash FlowN/A Book Value$5.09 per share Price / Book44.63Profitability EPS (Most Recent Fiscal Year)($2.16) Net Income$-54,570,000.00 Net Margins-28.50% Return on Equity-50.23% Return on Assets-22.26%Miscellaneous Employees748 Outstanding Shares27,402,000Market Cap$6.22 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $227.15 +4.61 (+2.07 %) (As of 09/25/2020 02:07 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IRTC News and Ratings via Email Sign-up to receive the latest news and ratings for IRTC and its competitors with MarketBeat's FREE daily newsletter. Irhythm Technologies (NASDAQ:IRTC) Frequently Asked Questions How has Irhythm Technologies' stock price been impacted by Coronavirus (COVID-19)? Irhythm Technologies' stock was trading at $85.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IRTC shares have increased by 165.5% and is now trading at $227.15. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Irhythm Technologies? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Irhythm Technologies. When is Irhythm Technologies' next earnings date? Irhythm Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Irhythm Technologies. How were Irhythm Technologies' earnings last quarter? Irhythm Technologies Inc (NASDAQ:IRTC) posted its quarterly earnings data on Thursday, August, 6th. The company reported ($0.75) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.84) by $0.09. The firm had revenue of $50.88 million for the quarter, compared to the consensus estimate of $42.18 million. Irhythm Technologies had a negative return on equity of 50.23% and a negative net margin of 28.50%. The company's quarterly revenue was down 3.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.43) earnings per share. View Irhythm Technologies' earnings history. What price target have analysts set for IRTC? 12 brokers have issued 1 year price targets for Irhythm Technologies' stock. Their forecasts range from $130.00 to $250.00. On average, they anticipate Irhythm Technologies' share price to reach $183.11 in the next twelve months. This suggests that the stock has a possible downside of 19.4%. View analysts' price targets for Irhythm Technologies. Are investors shorting Irhythm Technologies? Irhythm Technologies saw a decline in short interest during the month of August. As of August 14th, there was short interest totaling 3,040,000 shares, a decline of 20.0% from the July 30th total of 3,800,000 shares. Based on an average trading volume of 420,200 shares, the short-interest ratio is currently 7.2 days. View Irhythm Technologies' Short Interest. Who are some of Irhythm Technologies' key competitors? Some companies that are related to Irhythm Technologies include ResMed (RMD), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Penumbra (PEN), Tandem Diabetes Care (TNDM), Hill-Rom (HRC), Globus Medical (GMED), Nevro (NVRO), Haemonetics (HAE), ICU Medical (ICUI), Integra Lifesciences (IART), Inspire Medical Systems (INSP) and Inari Medical (NARI). View all competitors. What other stocks do shareholders of Irhythm Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Irhythm Technologies investors own include NVIDIA (NVDA), salesforce.com (CRM), Trade Desk (TTD), Alibaba Group (BABA), Square (SQ), Teladoc Health (TDOC), DexCom (DXCM), Advanced Micro Devices (AMD), Boeing (BA) and Cisco Systems (CSCO). Who are Irhythm Technologies' key executives? Irhythm Technologies' management team includes the following people: Mr. Kevin M. King, Pres, CEO & Director (Age 63)Mr. Matthew C. Garrett, Chief Financial Officer (Age 51)Mr. David A. Vort, Exec. VP of Sales (Age 53)Dr. Derrick Sung, Exec. VP of Strategy & Corp. Devel. (Age 46)Mr. Karim Karti, Chief Operating Officer (Age 50) When did Irhythm Technologies IPO? (IRTC) raised $76 million in an initial public offering (IPO) on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. What is Irhythm Technologies' stock symbol? Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC." Who are Irhythm Technologies' major shareholders? Irhythm Technologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.26%), William Blair Investment Management LLC (5.27%), Macquarie Group Ltd. (3.22%), Neuberger Berman Group LLC (2.79%), TimesSquare Capital Management LLC (2.27%) and New York State Common Retirement Fund (2.02%). Company insiders that own Irhythm Technologies stock include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Merz Cathleen Noel Bairey, Ralph Snyderman and Raymond W Scott. View institutional ownership trends for Irhythm Technologies. Which institutional investors are selling Irhythm Technologies stock? IRTC stock was sold by a variety of institutional investors in the last quarter, including Holocene Advisors LP, Bank of New York Mellon Corp, Macquarie Group Ltd., TimesSquare Capital Management LLC, Bellevue Group AG, Sei Investments Co., Great Lakes Advisors LLC, and Principal Financial Group Inc.. Company insiders that have sold Irhythm Technologies company stock in the last year include David A Vort, Kevin M King, Matthew C Garrett, Ralph Snyderman, and Raymond W Scott. View insider buying and selling activity for Irhythm Technologies. Which institutional investors are buying Irhythm Technologies stock? IRTC stock was purchased by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, FMR LLC, Blair William & Co. IL, Man Group plc, Columbus Circle Investors, Vanguard Group Inc., Federated Hermes Inc., and First Trust Advisors LP. View insider buying and selling activity for Irhythm Technologies. How do I buy shares of Irhythm Technologies? Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Irhythm Technologies' stock price today? One share of IRTC stock can currently be purchased for approximately $227.15. How big of a company is Irhythm Technologies? Irhythm Technologies has a market capitalization of $6.22 billion and generates $214.55 million in revenue each year. The company earns $-54,570,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Irhythm Technologies employs 748 workers across the globe. What is Irhythm Technologies' official website? The official website for Irhythm Technologies is www.irhythmtech.com. How can I contact Irhythm Technologies? Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
